The original author list was “Dongdong Luo, Xiaochun Liu, Leilei Jiang, Zhikun Guo, Yan Lv, Xiaochen Tian, Xiaoyan Wang, Shuxiang Cui, Shengbiao Wan, Xianjun Qu*, Ximing Xu*, and Xiaoyang Li*”. Co-corresponding author Xianjun Qu contributed the main idea on biological evaluation. Due to the importance of the biological work in this article, all the authors discussed the author list and would like to switch him to the last corresponding author. The author list for this paper should appear as “Dongdong Luo, Xiaochun Liu, Leilei Jiang, Zhikun Guo, Yan Lv, Xiaochen Tian, Xiaoyan Wang, Shuxiang Cui, Shengbiao Wan, Ximing Xu*, Xiaoyang Li*, and Xianjun Qu*”. This change is reflected in the authorship of this Correction. This article has not yet been cited by other publications.

中文翻译：

---

对“用于逆转结直肠癌 5-FU 耐药性的新型 S1PR2 拮抗剂的合理设计、合成和生物学评价”的更正

原作者名单为“罗冬冬、刘晓春、江蕾蕾、郭志坤、吕艳、田晓晨、王晓艳、崔树祥、万胜标、曲先军*、许锡明*、李晓阳*”。共同通讯作者曲先军贡献了生物学评价的主要思想。由于本文生物学工作的重要性，所有作者讨论了作者名单，希望将他切换为最后一位通讯作者。这篇论文的作者列表应显示为“Dongdong Luo, Xiaocun Liu, Leilei Jiang, Zhikun Guo, Yan Lv, Xiaochen Tian, Xiaoyan Wang, Shuxiang Cui, Shengbiao Wan, Ximing Xu*, Xiaoyang Li*, and Xianjun Qu*” . 此更改反映在本更正的作者身份中。这篇文章尚未被其他出版物引用。